Penn Capital Management Company LLC lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 15.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 207,362 shares of the specialty pharmaceutical company’s stock after purchasing an additional 27,646 shares during the period. Penn Capital Management Company LLC owned about 0.90% of ANI Pharmaceuticals worth $17,183,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Arrowstreet Capital Limited Partnership purchased a new stake in ANI Pharmaceuticals during the 3rd quarter worth $32,992,000. Ranger Investment Management L.P. purchased a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $28,406,000. Deutsche Bank AG acquired a new stake in shares of ANI Pharmaceuticals during the second quarter valued at about $26,775,000. Balyasny Asset Management L.P. grew its stake in shares of ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after acquiring an additional 276,233 shares in the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $21,372,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.
ANI Pharmaceuticals Stock Performance
Shares of ANI Pharmaceuticals stock opened at $72.83 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The firm’s 50-day simple moving average is $79.68 and its 200-day simple moving average is $78.65. The firm has a market cap of $1.67 billion, a PE ratio of 15.70 and a beta of 0.44.
Insider Buying and Selling
In other news, Director Thomas Haughey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the completion of the sale, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. The trade was a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the sale, the vice president directly owned 74,424 shares in the company, valued at approximately $5,617,523.52. This represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 24,387 shares of company stock worth $1,947,625. 8.10% of the stock is currently owned by insiders.
Analyst Ratings Changes
A number of research analysts recently commented on the company. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group cut their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Guggenheim reduced their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Finally, Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $105.83.
View Our Latest Stock Report on ANIP
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
- Five stocks we like better than ANI Pharmaceuticals
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
